<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912402</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-100-4/CAESURA</org_study_id>
    <nct_id>NCT03912402</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)</brief_title>
  <official_title>Multicenter Open-Label Single-Arm Trial of the Efficacy and Safety of BCD-100 in Combination With Platinum-Based Chemotherapy and Bevacizumab as First Line Treatment in Patients With Recurrent, Persistent or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics
      of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and
      bevacizumab as first-line treatment in patients with recurrent/persistent or metastatic
      cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two stages. At the first stage patients will receive up to 6
      cycles of BCD-100 in combination with platinum-based chemotherapy and bevacizumab or until
      unacceptable toxicity or disease progression. Patients who have demonstrated a positive
      antitumor effect (stabilization of the disease, partial or complete response) and who have no
      signs of unacceptable toxicity could continue to receive up to 12 cycles of maintenance
      therapy of BCD-100 in combination with bevacizumab or until unacceptable toxicity or disease
      progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2018</start_date>
  <completion_date type="Anticipated">July 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>ORR is defined as the percentage of the participants in the mITT population who have a Complete Response or a Partial Response. The ORR will be assessed by a blind independent central reviewer per RECIST 1.1 and iRECIST.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Progression-free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Cervical Cancer Metastatic</condition>
  <condition>Cervical Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>BCD-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-100 mg/kg Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-100</intervention_name>
    <description>Anti-PD-1 monoclonal antibody, IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (or carboplatin)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>BCD-100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form and the subject's ability to follow the Protocol
             requirements;

          2. Age: 18 years and older at the signing of the informed consent;

          3. Histologically verified (documented) adenomatous, adenosquamous, or squamous cervical
             cancer;

          4. Newly diagnosed metastatic cervical cancer or recurrent/persistent cervical cancer;

          5. Availability of archival histological tumor material (paraffin blocks) or consent to
             biopsy;

          6. ECOG performance status of 0 or 1;

          7. At least one RESICT 1.1-defined measurable target lesion confirmed by an independent
             review;

          8. Patients with reproductive potential must agree to practice acceptable methods of
             birth control throughout the entire trial period, starting from signing the informed
             consent and up to 24 weeks after the last dose of investigational product.

        Exclusion Criteria:

          1. Indications for radical therapy (surgical or radiotherapy);

          2. Prior systemic treatment for recurrent, secondarily progressive or initially
             metastatic disease;

          3. Chemotherapy, and / or radiation therapy, and / or chemo-radiation therapy for early
             stages of cervical cancer with disease progression / recurrence earlier than 6 months
             after the end of therapy;

          4. Patients with severe concomitant factors or the effects of their treatment
             (hemorrhage, perforation, fistula);

          5. Central nervous system (CNS) metastases;

          6. Concomitant diseases or conditions which pose a risk of AE development during study
             treatment:

               1. uncontrolled hypertension, defined as systolic &gt; 150 mm Hg or diastolic &gt; 90 mm
                  Hg;

               2. stable angina functional class III-IV;

               3. unstable angina or myocardial infarction less than 6 months prior to
                  randomization;

               4. NYHA Grade III-IV congestive heart failure;

               5. atopic asthma, Stage III-IV COPD, angioedema;

               6. severe respiratory failure;

               7. any other diseases which pose unacceptable risk of AE development during study
                  treatment in Investigator's opinion;

          7. Active or known or suspected autoimmune disease (subjects with Type 1 diabetes
             mellitus, hypothyroidism only requiring hormone replacement, or skin disorders
             (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to
             enroll);

          8. Condition requiring systemic treatment with either corticosteroids or other
             immunosuppressive medications within 14 days prior to randomization;

          9. Established diagnosis of coagulopathy and / or clinically significant bleeding,
             including nasal bleeding;

         10. The need for regular intake of anticoagulants, antiplatelet agents, platelet function
             inhibitors, or their course application less than 1 month before being included in the
             study;

         11. Hematologic disorders: neutrophils &lt;1500/mcl or platelets &lt;100 000/mcl or hemoglobin
             &lt;90 g/l;

         12. Renal disorders: creatinine ≥ 1.5 x UNL;

         13. Hepatic disorders: bilirubin ≥ 1.5 x UNL (excluding Gilbert's syndrome if bilirubin &lt;
             50 µmol/l) or AST/ALT ≥ 3 x UNL (excluding subjects with liver metastases if AST/ALT &lt;
             5 x UNL) or alkaline phosphatase ≥ 5 x UNL;

         14. Any anti-cancer therapy less than 28 days prior to randomization;

         15. Previous use of PD-1/PD-L1/PD-L2/CTLA-4 agent;

         16. Previous use of VEGF/VEGFR inhibitors, including bevacizumab, ramucirumab, aflibercept
             and tyrosine kinase inhibitors;

         17. Concomitant cancer (except for cervical carcinoma in situ after radical surgery or
             basal cell/ squamous cell carcinoma after radical surgery);

         18. Clinically significant (≥2 degree) peripheral neuropathy or hearing impairment;

         19. Any condition that prevents a patient from following the Protocol procedures
             (dementia, neurological or mental disorders, drug/alcohol abuse, etc.);

         20. Simultaneous participation in other clinical trials , participation in other clinical
             trials within 30 days prior to the first dose of the investigational product;

         21. Acute infection or the acute phase of chronic infection within 28 days prior the first
             dose of the investigational product;

         22. Active HBV/HCV/HIV infection, active syphilis;

         23. Patients unable to receive an IV infusions;

         24. Patients unable to receive an IV contrast agent;

         25. Hypersensitivity to any of the components of BCD-100, bevacizumab, paclitaxel,
             cisplatin (or carboplatin);

         26. Life expectancy less than 6 months;

         27. Significant adverse events (AE) of previous therapy excluding chronic and/or
             irreversible events which cannot affect study drug safety evaluation (e.g. alopecia);

         28. Pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman A Ivanov, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vice President R&amp;D, JSC BIOCAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariia S Shustova, MD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fedor B Kryukov, MD, PhD</last_name>
    <phone>+7-(812)-380-49-33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City Hospital No. 5</name>
      <address>
        <city>Barnaul</city>
        <state>Altai Krai</state>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis A Tancyirev, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangel'sk</city>
        <state>Arkhangelsk Oblast</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina N Nechaeva, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinsk Oblast</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya V Fadeeva, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Radiology Research Center</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluga Oblast</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya A Fetisova, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Oncologic Dispensary No. 1</name>
      <address>
        <city>Krasnodar</city>
        <state>Krasnodar Kari</state>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia M Makarova, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarsk Krai</state>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan A Zukov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Murmansk Regional Clinical Hospital named after P.A. Bayandina</name>
      <address>
        <city>Murmansk</city>
        <state>Murmansk Oblast</state>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny A Fomin, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <state>Omsk Oblast</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail V Dvorkin, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Oncology Center</name>
      <address>
        <city>Saransk</city>
        <state>Republic Of Mordovia</state>
        <zip>430005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel I Skopin, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Cente</name>
      <address>
        <city>Kazan</city>
        <state>Republic Of Tatarstan</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana F Shasamutdinova, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Petrov National Medical Research Center of Oncology (2)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Saint-Petersburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adilia F Urmancheeva, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;New Clinic&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol Krai</state>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery M Chistyakov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Oncology Center</name>
      <address>
        <city>Stavropol'</city>
        <state>Stavropol Krai</state>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana N Shkodenko, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncology Center</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk Oblast</state>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry E Emelyanov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay V Kislov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific and Practical Center named A.S. Loginova</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludmila G Zhukova, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin National Medical Research Center of Oncology (2)</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena V Artamonova, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin National Medical Research Center of Oncology</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey A Tulandin, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Medsi Group of Companies&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny V Ledin, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital No. 62</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniil L Stroyakovsky, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Modern Medical Technologies&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana V Odintsova, MD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;AB Medical Group&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197082</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timor T Andabekov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Petrov National Medical Research Center of Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Y Semiglazova, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir M Moiseenko, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

